The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pulmonary Langerhans Cell Histiocytosis (PLCH)

Rare smoking-related interstitial lung disease characterized by Langerhans cell proliferation forming nodules and cysts, leading to obstructive-restrictive lung disease and pneumothorax in young adult smokers.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Pulmonary Langerhans Cell Histiocytosis (PLCH)?

PLCH primarily affects young adults (mean age 30-40 years), with roughly equal sex distribution. Smoking is the major etiologic factor (>90% smokers; pathophysiology involves smoking-induced epithelial injury, cytokine release, and clonal Langerhans cell expansion). BRAF V600E and MAP2K1 mutations identified in subset, supporting clonal/neoplastic nature.

Pathology: peribronchiolar Langerhans cell aggregates with eosinophil infiltration form stellate nodules; bronchiolar wall destruction creates cavities; nodules evolve to thick-walled then thin-walled cysts; characteristic upper/middle lobe distribution with sparing of costophrenic angles distinguishes from emphysema and other cystic lung diseases.

Clinical course is variable: spontaneous regression with smoking cessation in some, stable disease, or progression to severe respiratory failure with cor pulmonale. Pulmonary hypertension develops in advanced disease, often disproportionate to lung function impairment.

Symptoms

Cough (often dry, persistent)
Dyspnea on exertion (gradual onset)
Spontaneous pneumothorax (10-25%)
Hemoptysis (uncommon)
Constitutional symptoms (fever, weight loss, fatigue) in 15-30%
Chest pain
Extrapulmonary manifestations (skin, bone, pituitary diabetes insipidus) in multisystem LCH

Risk Factors

Cigarette smoking (>90% of patients)
Young adult age (peak 20-40 years)
Slight male predominance in some series
Caucasian ancestry (more reported)
Cannabis smoking (reported association)
Genetic predisposition (BRAF V600E acquired mutation in 50%, MAP2K1 mutations)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent cough or dyspnea in young adult smoker
  • Spontaneous pneumothorax in young smoker
  • HRCT showing characteristic upper-lobe nodules and cysts
  • Hemoptysis or constitutional symptoms with cystic lung disease
  • Pulmonology referral for cystic lung disease evaluation

Treatment Methods

01
Diagnostic workup: HRCT chest (mid-upper lobe predominant nodules, cavitated nodules, irregular thin-walled cysts, sparing of costophrenic angles), pulmonary function tests (often mixed obstructive-restrictive, reduced DLCO), echocardiography for PH
02
Definitive diagnosis: characteristic HRCT often sufficient; bronchoalveolar lavage shows >5% CD1a+ Langerhans cells (sensitive); transbronchial or surgical lung biopsy if uncertain (CD1a+, CD207/Langerin+, S100+ Langerhans cells with characteristic peribronchiolar distribution)
03
BRAF V600E testing on biopsy if available — guides targeted therapy in severe/refractory cases
04
Smoking cessation: the single most important intervention; many patients stabilize or improve with cessation; nicotine replacement, varenicline, behavioral support
05
Mild-moderate disease: smoking cessation, watchful waiting with serial PFT and HRCT every 3-6 months initially; many cases stabilize
06
Symptomatic or progressive disease: prednisolone 0.5-1 mg/kg/day with taper, cladribine (2-CdA, 5 mg/m² days 1-5 every 4-6 weeks for 3-6 cycles) — efficacious in PLCH and multisystem LCH
07
Refractory or severe: cytarabine, vinblastine + prednisone (LCH protocols), targeted therapy with BRAF inhibitors (vemurafenib, dabrafenib) for BRAF V600E-positive disease, MEK inhibitors (cobimetinib, trametinib) for BRAF wild-type or MAP2K1 mutated
08
Pulmonary hypertension management: phosphodiesterase-5 inhibitors (sildenafil), endothelin receptor antagonists, prostanoids; PH disproportionate to lung function suggests vasculopathy component
09
Pneumothorax management: chest tube for first episode; pleurodesis or surgical pleurectomy for recurrent; avoid pleurectomy if lung transplant candidate
10
Lung transplantation: end-stage PLCH (FEV1 <30%, severe PH, severe disability); recurrence in transplanted lung described (10-20%) but often manageable
11
Multisystem LCH evaluation: skin examination, skeletal survey for lytic bone lesions, MRI brain for pituitary involvement (diabetes insipidus, anterior pituitary deficiency), endocrine evaluation
12
Multidisciplinary care: pulmonology, hematology-oncology (LCH expertise), endocrinology if multisystem, smoking cessation services, transplant team
13
Prognosis: highly variable — 5-year survival 70-85% overall; smokers who quit have better outcomes; predictors of progression include older age, FEV1 <80%, DLCO <80%, multiorgan involvement, severe PH

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.